Patients with high blood pressure and type 2 diabetes benefit from taking an angiotensin-convertingenzyme (ACE) inhibitor to lower blood pressure—even if they have no evidence of kidney or heart disease.
According to Reuters, Italian researchers studied 1,180 type 2s with hypertension as part of the BENEDICT trial. They found that treatment with the ACE inhibitor trandolapril, combined with another blood-pressure-lowering drug called verapamil (Veratran), delayed the onset of microalbuminuria, which is a build-up of the blood protein albumin in the urine that can signal kidney disease.
* * *
Source: Reuters, Journal of the American Society of Nephrology, December 2006